Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from DKS Co., Ltd. ( (JP:4461) ).
DKS Co. Ltd. and D. Western Therapeutics Institute, Inc. have announced positive results from their joint research project aimed at developing a treatment for dry eye. The collaboration, which began in December 2024, has confirmed the pharmacological effects of a synthesized compound in animal models, leading to an extension of their research agreement. This project is part of DKS’s efforts in its Life & Wellness segment to enhance research and development in the pharmaceutical field, with the goal of improving quality of life in an aging society. The joint research results will not impact the earnings forecast for the fiscal year ending March 2026.
The most recent analyst rating on (JP:4461) stock is a Buy with a Yen6677.00 price target. To see the full list of analyst forecasts on DKS Co., Ltd. stock, see the JP:4461 Stock Forecast page.
More about DKS Co., Ltd.
DKS Co. Ltd. is a chemical materials manufacturer recognized as a leader in industrial chemicals. Founded in 1909, the company initially developed a silkworm cocoon unwinding agent and has since focused on contributing to society through industry. DKS aims to be a unique and smart chemical partner, leveraging chemistry to address social issues.
Average Trading Volume: 123,150
Technical Sentiment Signal: Buy
Current Market Cap: Yen65.69B
For a thorough assessment of 4461 stock, go to TipRanks’ Stock Analysis page.